CERo Therapeutics doses seventh patient in Phase 1 CER-1236 trial
CERO•CERo Therapeutics said it dosed the seventh patient in its Phase 1 CER-1236 blood cancer trial on Nov. 3, 2026. The study has expanded to include myelodysplastic syndromes and myelofibrosis, in addition to acute myeloid leukemia.
1. Trial update
CERo Therapeutics said it dosed the seventh patient in its Phase 1 CER-1236 blood cancer trial. Previously reported findings showed no dose-limiting toxicities in the first three patients in the second cohort, and infused cells expanded following treatment. The study now includes myelodysplastic syndromes and myelofibrosis as well as acute myeloid leukemia; safety monitoring is ongoing.
